News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
GLP-1 drugs reach only 2-3% of Europeans who qualify, despite proven ROI
Obesity medications are delivering real clinical gains and productivity wins across Europe, but healthcare systems are moving too slowly to cover them. Here's why patient stigma and medical training gaps are the actual barriers.
Zai Lab's DLL3 Drug Wins EU Orphan Status for Lung Cancer
Zocilurtatug pelitecan secured EMA orphan drug designation for pulmonary neuroendocrine carcinomas. Three registration studies aim for completion by end of 2026.
Altaris buys Simulations Plus for $375M, merges with molecular design firm
Altaris is acquiring drug-development software maker Simulations Plus for $375M in cash, then combining it with portfolio company Chemical Computing Group to build an integrated biosimulation platform for pharma R&D.
BMS shows 96% response rate for GPRC5D CAR-T in myeloma phase I
Bristol Myers Squibb presented phase I data for arlocabtagene autoleucel targeting GPRC5D, achieving 96% overall response rate in relapsed myeloma patients. But efficacy in BCMA-resistant patients remains unproven.
AviadoBio Expands Gene-Silencing Patent to All Disease Areas
AviadoBio broadened its King's College London licence to deploy vMiX RNAi across cardiovascular, oncology, nephrology, and other fields beyond neurology. The platform silences disease genes with a single dose.
Eight in vivo CAR-T startups to watch in 2026
No approved in vivo CAR-T therapy exists yet, but eight companies from Umoja to Alaya.bio are in preclinical and clinical trials. Here's who is closest to the clinic and why they matter.
Single-Protein Imaging Maps Scramblase Speeds Up to 10,000 Lipids Per Second
Weill Cornell and Ruhr University researchers built a fluorescence microscopy platform to measure individual scramblase activity rates. The technique reveals why some proteins move lipids 100x faster than others.
Researchers Map 1.1M Gut Cells to Identify Crohn's Disease Drivers
Scientists analyzed over 1 million individual cells from Crohn's patients and healthy controls, revealing immune cells that fuel inflammation and a 'molecular scar' that persists after healing. Here's what the IBDverse dataset reveals about targeting new therapies.
Biomanufacturing Shifts from Capacity to Speed and Data
Danaher's bioprocessing summit revealed that competing in drug manufacturing now hinges on process intelligence and automation, not building larger facilities. Here's what biopharma manufacturers need to know.
KRAS Pancreatic Tumors Killed by Blocking Caspase-8 in Lab Models
University of Cologne researchers found that 90% of pancreatic cancers rely on a single protein to survive. Blocking it triggers cell death in mouse models and human tumor samples.
Merck bets $510M on Protillion's antibody discovery platform
Merck will pay up to $510 million in milestones to Protillion Biosciences for AI-driven drug discovery using its Prot-MaP platform, which tests millions of protein variants in 48 hours.
Corvus CEO targets blockbuster ITK inhibitor in cancer and autoimmune disease
Corvus Pharmaceuticals' lead candidate could replicate Rituxan's success across two therapeutic areas, CEO Richard Miller says. Here's what the ITK inhibitor program aims to achieve.